IBI 356
Alternative Names: IBI-356Latest Information Update: 25 Jan 2024
At a glance
- Originator Innovent Biologics
- Class Anti-inflammatories
- Mechanism of Action OX40 ligand modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis
- Preclinical Autoimmune disorders
Most Recent Events
- 05 Jan 2024 Phase-I clinical trials in Atopic dermatitis in China (unspecified route) (NCT06193434)
- 05 Jan 2024 Innovent Biologics plans a phase I trial for Atopic dermatitis in China in January 2024 (NCT06193434)
- 23 Aug 2023 Preclinical trials in Autoimmune disorders in China (unspecified route) before August 2023